CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility

Executive Summary

• CardioComm Solutions received TSX Venture Exchange approval for a $512,000 loan to fund development and commercialization of its Flagship ECG software platform.
• The financing is accompanied by the issuance of 345,600 bonus common shares and 6,912,000 common‑share purchase warrants (exercise price $0.05) to related‑party lenders.
• All securities are subject to a four‑month hold period expiring on March 11 2026; proceeds will be used for final product completion, user testing, market launch, and post‑launch support.

Key Details

• Loan amount: $512,000 (aggregate funding).
• Purpose of funds:
• Finalize the Flagship Product (GEMS FLEX & 14‑day Holter/Event LTCM ECG platform) for market release.
• Conduct structured user‑feedback reviews to refine usability and performance.
• Launch and market the product to targeted healthcare markets.
• Provide post‑launch customer support and installation services.
• Security issuance:
• Total bonus shares issued: 345,600 common shares.
• Total bonus warrants issued: 6,912,000 warrants (each exercisable for one share at $0.05).
• Allocation:
  • Xemxija Holdings Inc.: 280,000 shares + 5,600,000 warrants.
  • ITF Ventures Inc.: 65,600 shares + 1,312,000 warrants.
• Hold period: Four months; securities become tradable on or after March 11 2026.
• Related‑party nature: Lenders (Xemxija, ITF, and Etienne Grima) are insiders; transactions qualify for MI 61‑101 exemptions (no valuation or minority‑shareholder approval required).
• Regulatory compliance: Loan and bonus transactions exempt from formal valuation and shareholder‑approval thresholds under NI 61‑101. No material change report filed due to these exemptions.

Notable Quotes

• “The loan agreement provides the working capital needed to bring our Flagship Product to market, positioning CardioComm for a significant revenue boost.” – Etienne Grima, Chief Executive Officer.